Financial Health Report: Nurix Therapeutics Inc (NRIX)’s Ratios Tell a Tale

In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.

Nurix Therapeutics Inc (NASDAQ: NRIX) closed the day trading at $16.73 down -4.89% from the previous closing price of $17.59. In other words, the price has decreased by -$4.89 from its previous closing price. On the day, 0.65 million shares were traded.

Ratios:

For a better understanding of NRIX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.46 and its Current Ratio is at 6.46. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on December 10, 2024, initiated with a Buy rating and assigned the stock a target price of $35.

On December 06, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $35.

On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $35.UBS initiated its Buy rating on October 24, 2024, with a $35 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 31 ’25 when Ring Christine sold 5,760 shares for $19.95 per share. The transaction valued at 114,934 led to the insider holds 32,538 shares of the business.

CHRISTINE RING bought 5,760 shares of NRIX for $115,286 on Jan 31 ’25. On Jan 30 ’25, another insider, Ring Christine, who serves as the Chief Legal Officer of the company, sold 3,220 shares for $19.85 each. As a result, the insider received 63,929 and left with 32,538 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 23.27 while its Price-to-Book (P/B) ratio in mrq is 2.41.

Stock Price History:

Over the past 52 weeks, NRIX has reached a high of $29.56, while it has fallen to a 52-week low of $9.22. The 50-Day Moving Average of the stock is -14.09%, while the 200-Day Moving Average is calculated to be -19.77%.

Shares Statistics:

A total of 75.87M shares are outstanding, with a floating share count of 73.23M. Insiders hold about 3.50% of the company’s shares, while institutions hold 108.08% stake in the company.

Earnings Estimates

Currently, 13.0 analysts are dedicated to thoroughly evaluating and rating the performance of Nurix Therapeutics Inc (NRIX) in the stock market.The consensus estimate for the next quarter is -$0.76, with high estimates of -$0.55 and low estimates of -$0.94.

Analysts are recommending an EPS of between -$2.42 and -$3.82 for the fiscal current year, implying an average EPS of -$3.09. EPS for the following year is -$3.13, with 11.0 analysts recommending between -$1.62 and -$4.78.

Most Popular